Allergy Therapeutics PLC (GB:AGY)
LSE:AGY
Want to see GB:AGY full AI Analyst Report?
Top Page
Allergy Therapeutics
(LSE:AGY)
Select Model
Select Model
Rating:45Neutral
Price Target:
8.50 p
▼(-27.97% Downside)
Action:Reiterated
Date:02/20/26
The score is driven primarily by very weak financial performance (declining revenue, large losses, negative cash flows, and negative equity). Technicals are mixed with oversold signals but still negative momentum, and valuation is constrained by a negative P/E and no dividend support.
Positive Factors
Disease‑modifying immunotherapy
Allergy Therapeutics' core model targets disease modification rather than symptomatic relief. That structural positioning supports recurring treatment protocols, higher clinical differentiation and potential pricing power versus symptomatic care, creating durable commercial advantages if clinical efficacy is sustained.
Negative Factors
Declining revenue & large losses
Sustained revenue declines and deep net losses materially weaken reinvestment ability and strategic optionality. Persistent unprofitability reduces internal funding for trials and launches, increases reliance on external capital, and raises the risk that growth investments are curtailed over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Disease‑modifying immunotherapy
Allergy Therapeutics' core model targets disease modification rather than symptomatic relief. That structural positioning supports recurring treatment protocols, higher clinical differentiation and potential pricing power versus symptomatic care, creating durable commercial advantages if clinical efficacy is sustained.
Read all positive factors
Allergy Therapeutics (AGY) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£550.93M
Dividend YieldN/A
Average Volume (3M)460.33K
Price to Earnings (P/E)―
Beta (1Y)0.54
Revenue Growth2.94%
EPS Growth-32.00%
CountryUK
Employees612
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.01
Shares Outstanding6,332,530,000
10 Day Avg. Volume433,490
30 Day Avg. Volume460,334
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)-13.44
Price to Sales (P/S)6.88
P/FCF Ratio-11.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£68.00M
Allergy Therapeutics Business Overview & Revenue Model
Company Description
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-re...
How the Company Makes Money
null...
Allergy Therapeutics Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
30
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 57.29M | 55.04M | 55.20M | 59.59M | 72.77M | 84.33M |
| Gross Profit | 23.59M | 25.13M | 29.74M | 32.69M | 48.95M | 61.80M |
| EBITDA | -32.73M | -29.43M | -30.74M | -36.24M | -8.69M | 7.61M |
| Net Income | -48.97M | -40.13M | -40.22M | -43.07M | -13.78M | 2.89M |
Balance Sheet | ||||||
| Total Assets | 71.00M | 67.54M | 64.83M | 66.77M | 72.95M | 88.09M |
| Cash, Cash Equivalents and Short-Term Investments | 10.08M | 12.79M | 12.91M | 14.85M | 20.52M | 40.27M |
| Total Debt | 26.75M | 60.09M | 30.99M | 35.99M | 10.53M | 11.17M |
| Total Liabilities | 66.75M | 95.74M | 61.12M | 64.70M | 35.18M | 39.55M |
| Stockholders Equity | 4.25M | -28.19M | 3.71M | 2.07M | 37.77M | 48.53M |
Cash Flow | ||||||
| Free Cash Flow | -37.34M | -31.98M | -35.54M | -35.59M | -17.17M | 5.95M |
| Operating Cash Flow | -32.80M | -28.72M | -32.14M | -30.92M | -14.11M | 8.52M |
| Investing Cash Flow | -4.46M | -3.15M | -1.20M | -4.67M | -3.06M | -2.76M |
| Financing Cash Flow | 26.01M | 32.04M | 31.43M | 29.91M | -2.64M | -2.03M |
Allergy Therapeutics Technical Analysis
Negative
11.80
Price Trends
10.14
Negative
10.73
Negative
9.95
Negative
Market Momentum
-0.42
Positive
40.60
Neutral
13.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AGY, the sentiment is Negative. The current price of 11.8 is above the 20-day moving average (MA) of 9.48, above the 50-day MA of 10.14, and above the 200-day MA of 9.95, indicating a bearish trend. The MACD of -0.42 indicates Positive momentum. The RSI at 40.60 is Neutral, neither overbought nor oversold. The STOCH value of 13.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:AGY.
Allergy Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | £228.89M | 45.00 | 4.46% | 2.18% | 20.04% | -46.44% | |
60 Neutral | £79.19M | 13.88 | 7.82% | ― | ― | ― | |
59 Neutral | £3.01B | 10.71 | 15.83% | 4.16% | 3.84% | 8.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | £550.93M | -9.50 | 409.00% | ― | 2.94% | -32.00% | |
41 Neutral | £61.50M | -4.54 | 103.62% | ― | 49.81% | 52.94% |
* Healthcare Sector Average
GB:AGY
Allergy Therapeutics
8.90
1.50
20.27%
GB:ANCR
Animalcare
331.50
36.58
12.40%
GB:HIK
Hikma Pharmaceuticals
1,460.00
-555.18
-27.55%
GB:STX
Shield Therapeutics
5.80
3.22
125.24%
GB:VLG
Venture Life
66.00
12.25
22.79%
GB:BXP
Beximco Pharmaceuticals Limited Sponsored GDR RegS
42.50
4.00
10.39%
Allergy Therapeutics Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
Allergy Therapeutics boosts funding as Grassmuno launch and peanut vaccine advance
Positive
Mar 31, 2026
Allergy Therapeutics reported interim revenues of £36.3 million for the six months to 31 December 2025, up 7% despite phasing out unregistered products in Germany, but swung to an operating loss before RD of £2.5 million as it increased ...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and Financing
Allergy Therapeutics Reshapes Major Shareholding Ahead of Potential Hong Kong Listing
Positive
Mar 12, 2026
Allergy Therapeutics has reported an internal reorganisation within major shareholder ZQ Group, which transferred most of the company’s shares from SkyGem Acquisition to SkyGem International Holdings without changing ultimate beneficial owne...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.